PCSK9 inhibitors
Publication
, Journal Article
Farnier, M
Published in: Current Opinion in Lipidology
June 2013
Duke Scholars
Published In
Current Opinion in Lipidology
DOI
ISSN
0957-9672
Publication Date
June 2013
Volume
24
Issue
3
Start / End Page
251 / 258
Publisher
Ovid Technologies (Wolters Kluwer Health)
Related Subject Headings
- Cardiovascular System & Hematology
- 3205 Medical biochemistry and metabolomics
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
- 1101 Medical Biochemistry and Metabolomics
Citation
APA
Chicago
ICMJE
MLA
NLM
Farnier, M. (2013). PCSK9 inhibitors. Current Opinion in Lipidology, 24(3), 251–258. https://doi.org/10.1097/mol.0b013e3283613a3d
Farnier, Michel. “PCSK9 inhibitors.” Current Opinion in Lipidology 24, no. 3 (June 2013): 251–58. https://doi.org/10.1097/mol.0b013e3283613a3d.
Farnier M. PCSK9 inhibitors. Current Opinion in Lipidology. 2013 Jun;24(3):251–8.
Farnier, Michel. “PCSK9 inhibitors.” Current Opinion in Lipidology, vol. 24, no. 3, Ovid Technologies (Wolters Kluwer Health), June 2013, pp. 251–58. Crossref, doi:10.1097/mol.0b013e3283613a3d.
Farnier M. PCSK9 inhibitors. Current Opinion in Lipidology. Ovid Technologies (Wolters Kluwer Health); 2013 Jun;24(3):251–258.
Published In
Current Opinion in Lipidology
DOI
ISSN
0957-9672
Publication Date
June 2013
Volume
24
Issue
3
Start / End Page
251 / 258
Publisher
Ovid Technologies (Wolters Kluwer Health)
Related Subject Headings
- Cardiovascular System & Hematology
- 3205 Medical biochemistry and metabolomics
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
- 1101 Medical Biochemistry and Metabolomics